Portfolio

Astrocyte Pharmaceuticals is currently investigating several programs for the potential treatment of acute ischemic stroke, TBI, concussion, and other injuries to the brain.

The company’s lead candidate program AST-004 is a novel small molecule candidate currently in human Phase I clinical safety trials with an intravenous injection formulation suitable for administration by emergency professionals. An oral “field” formulation of AST-004 for mild TBI and concussions, and for chronic administration for neurodegenerative diseases is in preclinical development.

Candidate

Indication

Preclinical

Phase 1

Phase 2

Phase 3

AST-004

Acute Ischemic Stroke

AST-004

Severe-Moderate TBI

AST-004

Concussion / Mild TBI

AST-004

Alzheimer’s Disease

AST-008

Pain / Migraine

undisclosed

Multiple CNS Indications

Human Phase II patient clinical efficacy trials of AST-004 are planned to start in approximately a year, while subsequent Phase III studies, and New Drug Application (NDA) review by regulatory agencies such as the FDA typically take an additional 2-5 years to confirm results and approve the use of a new therapeutic.